Market Overview

UPDATE: Stifel Nicolaus Initiates Medtronic at Hold on Valuation

Share:
Related MDT
Following Intuitive Surgical's Solid Q2, Citi Asks What's Next
Medtronic Gets First-Ever FDA Approval For Cement-Augmented Pedicle Screws
Finding Some Of The Best-Quality Dividend Growth Stocks Using The Piotroski F Score (Seeking Alpha)

Stifel Nicolaus initiated coverage on Medtronic (NYSE: MDT) with a Hold rating.

Stifel Nicolaus commented, "We are initiating coverage of Medtronic, Inc. (MDT) with a Hold rating on the shares. Fair-to-reasonable valuation for the stock and lack of dramatic upside drivers keep us on the sidelines for the moment. With approximately 50% of Medtronic's business still in pressured "no growth" markets (Cardiac Rhythm Management and Spine) and limited room for further operating margin expansion, we suspect Medtronic's 10.8x forward P/E multiple is unlikely to expand significantly on a relative basis. With MDT shares already trading at the high end of the industry peer group on an EV/EBITDA basis, we prefer to wait for a better entry point on the shares."

Medtronic closed at $41.10 on Monday.

Latest Ratings for MDT

DateFirmActionFromTo
Jun 2016SunTrust Robinson HumphreyMaintainsBuy
Jun 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Jun 2016Deutsche BankMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!